Versorgungsforschung bei Psoriasis: Modell Deutschland

Zusammenfassung

Psoriasis vulgaris ist eine häufige, im klinischen Bild wie auch im Schweregrad sehr variable Erkrankung, die für viele Patienten eine große Last darstellt. Das therapeutische Spektrum ist breit und durch eine S3-Leitlinie konsentiert. Im weltweit größten Forschungsprogramm zur Versorgung der Psoriasis durch das Competenzzentrum Versorgungsforschung in der Dermatologie (CVderm) wurde in über 30 Einzelstudien ein differenziertes Profil der Versorgungsmerkmale erstellt. Darauf aufbauend wurde ein bundesweites Programm zur Verbesserung der Versorgung begonnen, das die Entwicklung regionaler Psoriasisnetze (PsoNet) sowie die Umsetzung der „Nationalen Versorgungsziele Psoriasis 2010 – 2015“ beinhaltet. Alle Maßnahmen werden wiederum versorgungswissenschaftlich begleitet.

Der vorliegende Artikel stellt das Vorgehen von der Versorgungsanalyse über die Zieldefinition bis zur Versorgungsgestaltung dar.

Abstract

Psoriasis is a common disease with a highly variable clinical presentation and disease severity. It is also associated with a significant burden of disease. Therapeutic possibilities are based on the German S3 guideline, which provides evidence-based treatment recommendations. In the worlds largest research program for psoriasis care, conducted by the “German Center for Health Services Research” in Hamburg (CVderm), health care provision has been described by the implementation of more than 25 different studies, conducted nationwide and addressing all aspects of psoriasis care. Based on the results, a program to improve psoriasis care in Germany has been launched under the auspices of the DDG and BVDD. Our action plan called for the establishment of decentralised regional psoriasis networks in order to improve quality of care (PsoNet) and the definition of treatment goals and national objectives in improving health care provision within the next 5 years. The activities are accompanied on a scientific level by the conduction of studies addressing the quality of psoriasis care throughout Germany.

• Literatur

• 1 Augustin M, Herberger K, Hintzen S et al. Prevalence of Skin Lesions and Need for Treatment in a Cohort of 90 880 Workers. Br J Dermatol 2011; 165: 865-873
• 2 Augustin M, Reich K, Reusch M et al. Health services research in psoriasis – the German approach. Dermatology 2009; 218: 293-301
• 3 Radtke MA, Reich K, Blome C et al. Evaluation of quality of care and guideline-compliant treatment in psoriasis. Development of a new system of quality indicators. Dermatology 2009; 219: 54-58
• 4 Schäfer I, Rustenbach SJ, Zimmer L et al. Prevalence of skin diseases in a cohort of 48,665 employees in Germany. Dermatology 2008; 217: 169-172
• 5 Augustin M, Reich K, Glaeske G et al. Comorbidity and age-related prevalence of psoriasis – analysis of health insurance data in Germany. Acta Derm Venereol 2010; 90: 147-151
• 6 Radtke MA, Reich K, Blome C et al. Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey. J Eur Acad Dermatol Venereol 2009; 23: 683-691
• 7 Reich K, Krüger K, Mössner R et al. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol 2009; 160: 1040-1047
• 8 Augustin M, Glaeske G, Radtke MA et al. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol 2010; 162: 633-636
• 9 Radtke MA, Fölster-Holst R, Beikert F et al. Juvenile psoriasis: rewarding endeavours in contemporary dermatology and pediatrics. G Ital Dermatol Venereol 2011; 146: 31-45
• 10 Augustin M, Radtke MA. Quality of life in psoriasis patients. Expert Rev Pharmacoecon Outcomes Res 2014; 14: 559-568
• 11 Augustin M, Krüger K, Radtke MA et al. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology 2008; 216: 366-372
• 12 Augustin M, Reich K, Blome C et al. Nail psoriasis in Germany: epidemiology and burden of disease. Br J Dermatol 2010; 163: 580-585
• 13 Augustin M, Blome C, Costanzo A et al. Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): Development and Validation of a Tool for Assessment of Nail Psoriasis Outcomes. Br J Dermatol 2014; 170: 591-598
• 14 Augustin M, Langenbruch AK, Gutknecht M et al. Quality of Life Measures for Dermatology: Definition, Evaluation, and Interpretation. Curr Derm Rep 2012; 1: 148-159
• 15 Radtke MA, Langenbruch AK, Schäfer I et al. Nail psoriasis as a severity indicator: results from the PsoReal study. Patient Relat Outcome Meas 2011; 2: 1-6
• 16 Schäfer I, Hacker J, Rustenbach SJ et al. Concordance of the Psoriasis Area and Severity Index (PASI) and patient-reported outcomes in psoriasis treatment. Eur J Dermatol 2010; 20: 62-67
• 17 Dubertret L, Mrowietz U, Ranki A et al. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 2006; 155: 729-736
• 18 Langenbruch AK, Radtke MA, Augustin M. Quality of psoriasis care from the patients’ perspective -- results of the national health care study PsoReal. Eur J Dermatol 2012; 22: 518-524
• 19 Kimball AB, Gieler U, Linder D et al. Psoriasis: is the Impairment to a Patient’s Life Cumulative?. J Eur Acad Dermatol Venereol 2010; 24: 989-1004
• 20 Augustin M. CLCI: Identifying Patients at Risk. In: Kimball AB, Linder MD, Itin P, et al., Hrsg. Dermatological Diseases and Cumulative Life Course Impairment. (Current Problems in Dermatology, Vol. 44). Basel: Karger; 2013: 74-81
• 21 Augustin M, Radtke MA. Health economic issues in psoriasis. Expert Review of Dermatology 2008; 3: 19-23
• 22 Berger K, Ehlken B, Kugland B et al. Cost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in Germany. J Dtsch Dermatol Ges 2005; 3: 511-518
• 23 Sohn S, Schoeffski O, Prinz J et al. Cost of Moderate to Severe Plaque Psoriasis in Germany: A Multicenter Cost-of-illness Study. Dermatology 2006; 212: 137-144
• 24 Radtke MA, Augustin M. Economic considerations in psoriasis management. Clin Dermatol 2008; 26: 424-431
• 25 Augustin M, Holland B, Dartsch D et al. Adherence in the treatment of psoriasis: a systematic review. Dermatology 2011; 222: 363-374
• 26 Radtke MA, Augustin J, Blome C et al. How do regional factors influence psoriasis patient care in Germany?. J Dtsch Dermatol Ges 2010; 8: 516-524
• 27 Augustin M, Schäfer I, Reich K et al. Systemic treatment with corticosteroids in psoriasis -- health care provision far beyond the S3-guidelines. J Dtsch Dermatol Ges 2011; 9: 833-838
• 28 Augustin M, Reich K, Glaeske G et al. Co-morbidity and age-related prevalence of psoriasis: Analysis of health insurance data in Germany. Acta Derm Venereol 2010; 90: 147-151
• 29 Augustin M, Radtke MA, Glaeske G et al. Epidemiology and Comorbidity in Children with Psoriasis and Atopic Eczema. Dermatology 2015; 231: 35-40
• 30 Radtke MA, Mrowietz U, Feuerhahn J et al. Early detection of comorbidity in psoriasis: recommendations of the National Conference on Healthcare in Psoriasis. J Dtsch Dermatol Ges 2015; 13: 674-689
• 31 Wohlrab J, Fiedler G, Gerdes S et al. Recommendations for detection of individual risk for comorbidities in patients with psoriasis. Arch Dermatol Res 2013; 305: 91-98
• 32 Augustin M, Glaeske G, Schaefer I et al. Versorgungsprozesse der Psoriasis in Deutschland – Langzeitanalyse von Sekundärdaten der gesetzlichen Krankenversicherung [Processes of Psoriasis Health Care in Germany – Long-Term Analysis of Data from the Statutory Health Insurances]. J Dtsch Dermatol Ges 2012; 10: 648-655
• 33 Augustin M, Reich K, Glaeske G et al. Arzneimittelversorgung von Kindern mit Psoriasis in Deutschland. J Dtsch Dermatol Ges 2013; 11: 751-755
• 34 Strömer K, Gass S. Sicherstellung der Versorgung – Psoriasis aus Sicht des Berufsverbandes der Deutschen. gpk Sonderausgabe Gesellschaftspolitische Kommentare 2014; 1: 29-30
• 35 Augustin M, Radtke MA, Zschocke I et al. The Patient Benefit Index: a Novel Approach in Patient-defined Outcomes Measurement for Skin Diseases. Arch Dermatol Res 2009; 301: 561-571
• 36 Blome C, Simianer S, Purwins S et al. Time needed for treatment is the major predictor of quality of life in psoriasis. Dermatology 2010; 221: 154-1549
• 37 Feuerhahn J, Blome C, Radtke MA et al. Validation of the Patient Benefit Index for the Assessment of Patient-Relevant Benefit in the Treatment of Psoriasis. Arch Dermatol Res 2012; 304: 433-441
• 38 Radtke MA, Reich K, Spehr C et al. Treatment Goals in Psoriasis Routine Care. Archives of Dermatological Research 2015; 307: 445-449
• 39 Radtke MA, Schäfer I, Blome C et al. Patient benefit index (PBI) in the treatment of psoriasis – results of the National Care Study “PsoHealth”. Eur J Dermatol 2013; 23: 212-217